Ghisallo Capital Management LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Ghisallo Capital Management LLC bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,100,000 shares of the company’s stock, valued at approximately $8,250,000. Ghisallo Capital Management LLC owned 0.39% of Recursion Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Dimensional Fund Advisors LP raised its stake in shares of Recursion Pharmaceuticals by 152.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,137,110 shares of the company’s stock valued at $21,079,000 after purchasing an additional 1,291,946 shares during the period. UBS Group AG lifted its holdings in Recursion Pharmaceuticals by 101.9% in the 4th quarter. UBS Group AG now owns 691,911 shares of the company’s stock worth $6,822,000 after buying an additional 349,232 shares in the last quarter. CIBC Private Wealth Group LLC purchased a new position in Recursion Pharmaceuticals in the 4th quarter valued at about $1,348,000. Mubadala Investment Co PJSC acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at about $128,041,000. Finally, Vanguard Group Inc. increased its position in shares of Recursion Pharmaceuticals by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company’s stock worth $154,459,000 after acquiring an additional 158,376 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Needham & Company LLC reduced their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $6.17 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.97 and a 12-month high of $15.74. The business’s fifty day moving average price is $6.95 and its 200 day moving average price is $8.12. The stock has a market capitalization of $1.73 billion, a PE ratio of -3.86 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same period last year, the firm posted ($0.38) earnings per share. The company’s quarterly revenue was up 30.9% on a year-over-year basis. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Insider Activity at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total transaction of $83,792.04. Following the completion of the transaction, the director now owns 7,167,110 shares of the company’s stock, valued at $52,463,245.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $7.32, for a total value of $83,792.04. Following the completion of the transaction, the director now directly owns 7,167,110 shares of the company’s stock, valued at approximately $52,463,245.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares in the company, valued at $3,647,966. The disclosure for this sale can be found here. Insiders sold 231,682 shares of company stock worth $1,632,044 in the last 90 days. 15.75% of the stock is currently owned by company insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.